INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitational
- A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available
- The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease
- INMB received a $1 million grant from the Alzheimer’s Association to fund XPro1595 research and upcoming clinical trials in patients with Alzheimer’s disease
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements at the upcoming Ninth Annual LD Micro Invitational scheduled to take place at the Luxe Sunset Boulevard Hotel, June 4-5 in Bel-Air, California. Co-founder and CFO David Moss will lead INmune Bio’s presentation, which is set for June 5 at 10:20 a.m. PT, and participate in one-on-one meetings at the event, according to a news release (http://nnw.fm/x5YCi).
INmune Bio is pursuing several novel drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://nnw.fm/dIP4x). Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases, including cancer and Alzheimer’s disease/dementia, which currently affect an estimated 5.8 million Americans, according to the Alzheimer’s Association (http://nnw.fm/w44kY).
INmune Bio has been recognized by the Alzheimer’s Association with a ‘Part the Cloud’ award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease. INmune Bio expects to initiate an XPro1595 phase I clinical trial in patients with Alzheimer’s disease during the summer of 2019.
INmune Bio is also advancing several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” of the body’s innate immune system, making it a powerful weapon in the fight against cancer (http://nnw.fm/s7G0W). INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.
INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://nnw.fm/Af4Jb).
INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://nnw.fm/tRpQ7). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.
“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” Moss said in a news release, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.
To schedule a one-on-one meeting with INmune Bio and Moss anytime during the LD Micro Invitational, contact KCSA Strategic Communications at INmune@kcsa.com
For more information, visit the company’s website at www.INmuneBio.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available
- The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease
- INMB received a $1 million grant from the Alzheimer’s Association to fund XPro1595 research and upcoming clinical trials in patients with Alzheimer’s disease
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements at the upcoming Ninth Annual LD Micro Invitational scheduled to take place at the Luxe Sunset Boulevard Hotel, June 4-5 in Bel-Air, California. Co-founder and CFO David Moss will lead INmune Bio’s presentation, which is set for June 5 at 10:20 a.m. PT, and participate in one-on-one meetings at the event, according to a news release (http://nnw.fm/x5YCi).
INmune Bio is pursuing several novel drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://nnw.fm/dIP4x). Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases, including cancer and Alzheimer’s disease/dementia, which currently affect an estimated 5.8 million Americans, according to the Alzheimer’s Association (http://nnw.fm/w44kY).
INmune Bio has been recognized by the Alzheimer’s Association with a ‘Part the Cloud’ award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease. INmune Bio expects to initiate an XPro1595 phase I clinical trial in patients with Alzheimer’s disease during the summer of 2019.
INmune Bio is also advancing several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” of the body’s innate immune system, making it a powerful weapon in the fight against cancer (http://nnw.fm/s7G0W). INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.
INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://nnw.fm/Af4Jb).
INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://nnw.fm/tRpQ7). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.
“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” Moss said in a news release, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.
To schedule a one-on-one meeting with INmune Bio and Moss anytime during the LD Micro Invitational, contact KCSA Strategic Communications at INmune@kcsa.com
For more information, visit the company’s website at www.INmuneBio.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
